Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
magazineConvatec shares start moving up after it hits half a billion of sales in first quarter
ConvaTec (CTEC) 223.8p
Gain to date: 9.3%
Original entry point: Buy at 204.6p, 23 December 2020
Shares in medical products firm Convatec (CTEC) are finally picking up, having been a laggard earlier this year thanks to a mix of sentiment shifting in favour of value stocks and concerns around pandemic-related disruption to the business.
Its latest update (29 Apr) seems to have won back the market’s attention. The company reported an 8.7% rise in revenue in the first quarter to $500 million, led by growth in its advanced wound care and infusion care business.
Advanced wound care revenue was up 8.8% on a reported basis, while ostomy care, its second largest business was up by 6.7%. Infusion care revenue increased by 13.9%, and continence and critical care revenue was up by 7.4%.
The company has maintained its full year outlook, citing ongoing macro uncertainties. For 2021, organic revenue growth is expected to be between 3% and 4.5%.
Numis analyst Paul Cudden says the numbers ‘provide further evidence that the turnaround has stuck’, adding that guidance looks ‘very conservative’.
SHARES SAYS: Convatec should benefit through the remainder of 2021 as elective surgeries delayed by Covid proceed. As a result, there’s a good chance of earnings upgrades. Buy.
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
